Do analysts rate CARM or EVGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer EVGN or INAB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, EVGN or INAB?

Evogene has higher revenue and earnings than IN8bio. IN8bio is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evogene $3.85M 0.88 -$8.48M -$0.91 N/A IN8bio N/A N/A -$19.44M -$1.62 N/A

Is EVGN or INAB more profitable?

IN8bio has a net margin of 0.00% compared to Evogene's net margin of -694.18%. IN8bio's return on equity of -91.18% beat Evogene's return on equity. Company Net Margins Return on Equity Return on Assets Evogene -694.18% -156.53% -86.80% IN8bio N/A -91.18% -76.93%

Do analysts prefer HIND or EVGN?

Vyome currently has a consensus price target of $3.50, indicating a potential upside of 77.66%. Given Vyome's stronger consensus rating and higher possible upside, equities research analysts plainly believe Vyome is more favorable than Evogene. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vyome 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, HIND or EVGN?

Evogene has higher revenue and earnings than Vyome. Vyome is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vyome $320K 43.22 -$10.26M -$3.37 N/A Evogene $3.85M 0.88 -$8.48M -$0.91 N/A

Is HIND or EVGN more profitable?

Evogene has a net margin of -694.18% compared to Vyome's net margin of -3,024.84%. Evogene's return on equity of -156.53% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets Vyome -3,024.84% -197.33% -138.14% Evogene -694.18% -156.53% -86.80%

Do analysts rate EVGN or SYBX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synlogic 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, EVGN or SYBX?

Evogene has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evogene $3.85M 0.88 -$8.48M -$0.91 N/A Synlogic $8K 1,622.99 -$23.36M -$0.06 N/A

Is EVGN or SYBX more profitable?

Synlogic has a net margin of 0.00% compared to Evogene's net margin of -694.18%. Synlogic's return on equity of -26.47% beat Evogene's return on equity. Company Net Margins Return on Equity Return on Assets Evogene -694.18% -156.53% -86.80% Synlogic N/A -26.47% -18.00%

Does the media favor EVGN or SYBX?

In the previous week, Evogene had 4 more articles in the media than Synlogic. MarketBeat recorded 5 mentions for Evogene and 1 mentions for Synlogic. Synlogic's average media sentiment score of 0.75 beat Evogene's score of 0.36 indicating that Synlogic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evogene 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Synlogic 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TPST or EVGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor TPST or EVGN?

In the previous week, Evogene had 2 more articles in the media than Tempest Therapeutics. MarketBeat recorded 5 mentions for Evogene and 3 mentions for Tempest Therapeutics. Evogene's average media sentiment score of 0.36 beat Tempest Therapeutics' score of 0.26 indicating that Evogene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tempest Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evogene 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Evogene (EVGN) Competitors

$0.38 -0.01 (-3.64%)

As of 12:43 PM Eastern

Compare

EVGN vs. CARM, INAB, HIND, SYBX, and TPST

Should you buy Evogene stock or one of its competitors? Evogene's main competitors and comparable companies include Carisma Therapeutics (CARM), IN8bio (INAB), Vyome (HIND), Synlogic (SYBX), and Tempest Therapeutics (TPST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Evogene compare to Carisma Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Carisma Therapeutics has a beta of -9.6, indicating that its share price is 1,060% less volatile than the broader market. Comparatively, Evogene has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 7.4% of Evogene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Carisma Therapeutics has a net margin of -254.28% compared to Evogene's net margin of -694.18%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Evogene	-694.18%	-156.53%	-86.80%

In the previous week, Evogene had 5 more articles in the media than Carisma Therapeutics. MarketBeat recorded 5 mentions for Evogene and 0 mentions for Carisma Therapeutics. Evogene's average media sentiment score of 0.36 beat Carisma Therapeutics' score of 0.00 indicating that Evogene is being referred to more favorably in the news media.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Evogene	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00
Evogene	$3.85M	0.88	-$8.48M	-$0.91	N/A

Summary

Evogene beats Carisma Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Evogene compare to IN8bio?

Evogene (NASDAQ:EVGN) and IN8bio (NASDAQ:INAB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Evogene has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market. Comparatively, IN8bio has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market.

IN8bio has a net margin of 0.00% compared to Evogene's net margin of -694.18%. IN8bio's return on equity of -91.18% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-694.18%	-156.53%	-86.80%
IN8bio	N/A	-91.18%	-76.93%

In the previous week, Evogene had 4 more articles in the media than IN8bio. MarketBeat recorded 5 mentions for Evogene and 1 mentions for IN8bio. IN8bio's average media sentiment score of 0.91 beat Evogene's score of 0.36 indicating that IN8bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Evogene	Neutral
IN8bio	Positive

Evogene has higher revenue and earnings than IN8bio. IN8bio is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	0.88	-$8.48M	-$0.91	N/A
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

10.4% of Evogene shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 7.4% of Evogene shares are held by company insiders. Comparatively, 14.5% of IN8bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

IN8bio beats Evogene on 8 of the 13 factors compared between the two stocks.

How does Evogene compare to Vyome?

Vyome (NASDAQ:HIND) and Evogene (NASDAQ:EVGN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Vyome has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, Evogene has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market.

22.1% of Vyome shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 33.0% of Vyome shares are held by company insiders. Comparatively, 7.4% of Evogene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Evogene had 4 more articles in the media than Vyome. MarketBeat recorded 5 mentions for Evogene and 1 mentions for Vyome. Vyome's average media sentiment score of 1.82 beat Evogene's score of 0.36 indicating that Vyome is being referred to more favorably in the media.

Company	Overall Sentiment
Vyome	Very Positive
Evogene	Neutral

Evogene has a net margin of -694.18% compared to Vyome's net margin of -3,024.84%. Evogene's return on equity of -156.53% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vyome	-3,024.84%	-197.33%	-138.14%
Evogene	-694.18%	-156.53%	-86.80%

Evogene has higher revenue and earnings than Vyome. Vyome is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$320K	43.22	-$10.26M	-$3.37	N/A
Evogene	$3.85M	0.88	-$8.48M	-$0.91	N/A

Vyome currently has a consensus price target of $3.50, indicating a potential upside of 77.66%. Given Vyome's stronger consensus rating and higher possible upside, equities research analysts plainly believe Vyome is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Vyome beats Evogene on 8 of the 15 factors compared between the two stocks.

How does Evogene compare to Synlogic?

Evogene (NASDAQ:EVGN) and Synlogic (NASDAQ:SYBX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

Evogene has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, Synlogic has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

10.4% of Evogene shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 7.4% of Evogene shares are owned by company insiders. Comparatively, 2.6% of Synlogic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Evogene has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	0.88	-$8.48M	-$0.91	N/A
Synlogic	$8K	1,622.99	-$23.36M	-$0.06	N/A

In the previous week, Evogene had 4 more articles in the media than Synlogic. MarketBeat recorded 5 mentions for Evogene and 1 mentions for Synlogic. Synlogic's average media sentiment score of 0.75 beat Evogene's score of 0.36 indicating that Synlogic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evogene	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Synlogic	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synlogic	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Synlogic has a net margin of 0.00% compared to Evogene's net margin of -694.18%. Synlogic's return on equity of -26.47% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-694.18%	-156.53%	-86.80%
Synlogic	N/A	-26.47%	-18.00%

Summary

Synlogic beats Evogene on 7 of the 13 factors compared between the two stocks.

How does Evogene compare to Tempest Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and Evogene (NASDAQ:EVGN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

In the previous week, Evogene had 2 more articles in the media than Tempest Therapeutics. MarketBeat recorded 5 mentions for Evogene and 3 mentions for Tempest Therapeutics. Evogene's average media sentiment score of 0.36 beat Tempest Therapeutics' score of 0.26 indicating that Evogene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tempest Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evogene	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Evogene has higher revenue and earnings than Tempest Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A
Evogene	$3.85M	0.88	-$8.48M	-$0.91	N/A

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 36.2% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 7.4% of Evogene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tempest Therapeutics has a net margin of 0.00% compared to Evogene's net margin of -694.18%. Evogene's return on equity of -156.53% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-576.56%	-134.99%
Evogene	-694.18%	-156.53%	-86.80%

Tempest Therapeutics has a beta of -1.73, indicating that its share price is 273% less volatile than the broader market. Comparatively, Evogene has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Evogene beats Tempest Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Evogene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVGN vs. The Competition

Export

Metric	Evogene	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.28M	$3.89B	$7.28B	$13.01B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-0.41	12.99	275.44	25.42
Price / Sales	0.85	1,141.69	559.80	78.81
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	0.27	16.88	10.66	5.96
Net Income	-$8.48M	-$22.65M	$3.50B	$380.62M
7 Day Performance	-8.43%	-5.64%	-3.65%	-3.75%
1 Month Performance	-24.01%	-13.53%	-8.06%	-6.62%
1 Year Performance	-71.08%	6.87%	2.58%	-4.38%

Evogene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVGN Evogene	1.0719 of 5 stars	$0.38 -3.6%	N/A	-69.5%	$3.28M	$3.85M	N/A	52	Gap Down
CARM Carisma Therapeutics	N/A	$0.00 flat	N/A	-98.9%	$21K	$10.77M	0.00	20
INAB IN8bio	1.9286 of 5 stars	$1.39 -2.1%	$4.00 +187.8%	-45.6%	$14.00M	N/A	N/A	18
HIND Vyome	2.5013 of 5 stars	$2.06 +6.7%	$3.50 +69.9%	-60.7%	$13.55M	$129.73K	N/A	18	Positive News
SYBX Synlogic	N/A	$1.07 -2.7%	N/A	-31.6%	$13.47M	$8K	N/A	80	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVGN) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evogene (EVGN) Competitors

EVGN vs. CARM, INAB, HIND, SYBX, and TPST

How does Evogene compare to Carisma Therapeutics?

Summary

How does Evogene compare to IN8bio?

Summary

How does Evogene compare to Vyome?

Summary

How does Evogene compare to Synlogic?

Summary

How does Evogene compare to Tempest Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN vs. The Competition

Evogene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evogene (EVGN) Competitors

EVGN vs. CARM, INAB, HIND, SYBX, and TPST

How does Evogene compare to Carisma Therapeutics?

Which has more risk & volatility, CARM or EVGN?

Do insiders & institutionals believe in CARM or EVGN?

Is CARM or EVGN more profitable?

Does the media refer more to CARM or EVGN?

Do analysts rate CARM or EVGN?

Which has higher earnings and valuation, CARM or EVGN?

Summary

How does Evogene compare to IN8bio?

Which has more volatility and risk, EVGN or INAB?

Is EVGN or INAB more profitable?

Does the media favor EVGN or INAB?

Which has preferable valuation & earnings, EVGN or INAB?

Do analysts prefer EVGN or INAB?

Do insiders and institutionals believe in EVGN or INAB?

Summary

How does Evogene compare to Vyome?

Which has more volatility and risk, HIND or EVGN?

Do insiders and institutionals have more ownership in HIND or EVGN?

Does the media refer more to HIND or EVGN?

Is HIND or EVGN more profitable?

Which has preferable earnings & valuation, HIND or EVGN?

Do analysts prefer HIND or EVGN?

Summary

How does Evogene compare to Synlogic?

Which has more volatility & risk, EVGN or SYBX?

Do institutionals and insiders believe in EVGN or SYBX?

Which has higher earnings & valuation, EVGN or SYBX?

Does the media favor EVGN or SYBX?

Do analysts rate EVGN or SYBX?

Is EVGN or SYBX more profitable?

Summary

How does Evogene compare to Tempest Therapeutics?

Does the media favor TPST or EVGN?

Which has higher valuation and earnings, TPST or EVGN?

Do institutionals and insiders believe in TPST or EVGN?

Is TPST or EVGN more profitable?

Which has more risk and volatility, TPST or EVGN?

Do analysts prefer TPST or EVGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN vs. The Competition

Evogene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools